$2.62
4.80% today
Nasdaq, Apr 02, 09:48 pm CET
ISIN
US2936021086
Symbol
ENSC
Sector
Industry

Ensysce Biosciences Inc Stock price

$2.64
-2.69 50.47% 1M
-0.87 24.88% 6M
-5.50 67.57% YTD
-9.51 78.27% 1Y
-4,029.36 99.93% 3Y
-39,273.36 99.99% 5Y
-34,737.36 99.99% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.14 5.60%
ISIN
US2936021086
Symbol
ENSC
Sector
Industry

Key metrics

Market capitalization $3.51m
Enterprise Value $-30.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.00
EV/Sales (TTM) EV/Sales -0.01
P/S ratio (TTM) P/S ratio 0.67
P/B ratio (TTM) P/B ratio 0.91
Revenue growth (TTM) Revenue growth 133.58%
Revenue (TTM) Revenue $5.21m
EBIT (operating result TTM) EBIT $-6.73m
Free Cash Flow (TTM) Free Cash Flow $-7.50m
Cash position $3.50m
EPS (TTM) EPS $-13.18
Short interest 1.60%
Show more

Is Ensysce Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Ensysce Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Ensysce Biosciences Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Ensysce Biosciences Inc:

Buy
100%

Financial data from Ensysce Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
5.21 5.21
134% 134%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.72 4.72
12% 12%
91%
- Research and Development Expense 7.22 7.22
5% 5%
139%
-6.73 -6.73
37% 37%
-129%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -6.73 -6.73
37% 37%
-129%
Net Profit -7.99 -7.99
25% 25%
-153%

In millions USD.

Don't miss a Thing! We will send you all news about Ensysce Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ensysce Biosciences Inc Stock News

Neutral
Accesswire
2 days ago
SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has entered into definitive agreements, providing the Company with an aggregate gross proceeds of...
Neutral
Accesswire
15 days ago
~ Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~ ~ Panel Discussion Posted to Ensysce's Corporate Website ~ SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid a...
Neutral
Accesswire
23 days ago
Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CA / ACCESS Newswire / March 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing ...
More Ensysce Biosciences Inc News

Company Profile

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on proprietary technology platforms to develop safer prescription drugs. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms, are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company is headquartered in La Jolla, CA.

Head office United States
CEO D. Kirkpatrick
Employees 9
Founded 2003
Website www.ensysce.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today